Treatment of schizophrenia disorders using combination therapy

The present specification discloses a combination therapy comprising one or more activators of alpha-7 nicotinic acetylcholine receptor activity having 5-HT3 receptor inhibitory activity and one or more activators of 5-HT3 receptor activity for use in the treatment of schizophrenia disorders, and methods of treating schizophrenia disorders by administering a combination therapy comprising one or more activators of alpha-7 nicotinic acetylcholine receptor activity and one or more activators of 5-HT3 receptor activity having 5-HT3 receptor inhibitory activity. 本说明书公开了包括具有5-HT3受体抑制活性的一种或更多种α-7烟碱型乙酰胆碱受体活性活化剂和一种或更多种5-HT3受体活性活化剂的组合疗法，用于在治疗精神分裂症性障碍中使用，以及通过施用包括具有5-HT3受体抑制活性的一种或更多种α-7烟碱型乙酰胆碱受体活性活化剂和一种或更多种5-HT3受体活性活化剂的组合疗法治疗精神分裂症性障碍的方法。